C0279025||Adjuvant Endocrine Therapy
C0678222||Breast Cancer
C0282574||e-Health Approach
C0087111||Treatment
C0282574||OPTIMUM
C1257890||Group
C0031928||Pilot Study
C0043210||women
C1563119||hormone receptor positive
C0678222||breast cancer
C0279025||adjuvant endocrine therapy
C0279025||adjuvant endocrine therapy
C0376405||Nonadherence
C0043210||women
C0279025||adjuvant endocrine therapy
C0282574||eHealth tool
C0282574||OPTIMUM
C0936012||real-time analysis
C0086388||health administrative claims data
C0871685||clinicians
C0086388||real-time eHealth alert delivered
C0279025||adjuvant endocrine therapy
C0457454||discontinuation
C0279025||adjuvant endocrine therapy
C0457454||discontinuation
C0086388||eHealth alerts
C0237607||practices
C1533734||administration
C0279025||adjuvant endocrine therapy
C0006826||cancer
C0086388||care teams
C1257890||group
C0031928||pilot study
C0019994||McGill University-affiliated hospitals
C0019994||Royal Victoria Hospital
C0019994||St. Mary's Hospital
C1516879||enrolled
C1522577||Follow-up
C0018724||Health care professionals
C0184661||intervention site
C0282574||eHealth tool
C0243095||real-time medical events
C0279025||adjuvant endocrine therapy
C0457454||discontinuation
C0279025||adjuvant endocrine therapy
C0457454||discontinuation
C0279025||adjuvant endocrine therapy
C0457454||discontinuation
C0392366||Tests
C0814896||significance level
C0279025||adjuvant endocrine therapy
C0457454||discontinuation
C0279025||adjuvant endocrine therapy
C0086388||care team actions
C0184661||intervention site
C0679646||Participant
C1516879||enrollment
C0015730||feasibility
C0282574||eHealth tool
C0376636||management
C0678222||breast cancer
C0332167||high-risk
C1257890||population
C0184661||intervention
C0279025||adjuvant endocrine therapy
C0457454||discontinuation